1 / 26

Castrate-resistant prostate cancer (CRPC)

Castrate-resistant prostate cancer (CRPC). Castrate-resistant prostate cancer (CRPC). disease progression despite androgen depletion therapy (ADT) present as : continuous rise in PSA progression of pre-existing disease appearance of new metastases. "Castrate resistant ".

paytah
Download Presentation

Castrate-resistant prostate cancer (CRPC)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Castrate-resistant prostate cancer (CRPC)

  2. Castrate-resistant prostate cancer (CRPC) • disease progression despite androgen depletion therapy (ADT) • present as : • continuous rise in PSA • progression of pre-existing disease • appearance of new metastases

  3. "Castrate resistant" • growing despite the hormone therapy with testosterone at "castrate" levels. • Still helped by other forms of hormone therapy

  4. "hormone refractory" • no response to any type of hormone therapy, including the newer medicines.

  5. Combined androgen blockade (CAB) orchiectomy LHRH agonist + anti-androgen LHRH antagonist • Superior tomonotherapy

  6. CRPC mechanism

  7. Management of CRPC

  8. Secondary hormonal manipulations • In relatively asymptomatic CRPC: First Line

  9. Monotherapytreated (LHRH agonist or orchidectomy): • Total androgen blockade (TAB) with testosterone antagonists, such as bicalutamide , … • ( PSA responses in 30% to 35% ) First Line

  10. TAB patients • First discontinue the antiandrogen: exclude an antiandrogen withdrawal response (AAWD). • Not response? • Second line hormonetherapy (adrenal) First Line

  11. ketoconazole • weak inhibitor of CYP11A and CYP17A • suppresses the synthesis of adrenal and tumor tissue androgens. • nausea and hepatotoxicity • must be given with replacement steroids • PSA response rates around 50%. First Line

  12. First-line systemic chemotherapy • In CRPC with detectable macroscopic metastatic disease • improve survival for CRPC • 1996, mitoxantrone was the first chemotherapy second Line

  13. Mitoxantrone • a semi-synthetic anthracycline • first chemotherapy to be approved by (FDA) • no survival benefit in two phase 3 trials • significant improvements of pain second Line

  14. late 1990 s, the microtubulestabilizingtaxane agents showed promise second Line

  15. Docetaxel • a taxane drug :polymerization of microtubules and phosphorylation of bcl-2 protein • docetaxel 75 mg/m2 intravenously every 3 weeks +5 mg oral prednisone twice daily • the standard of care for men with CRPC with detectable metastatic disease. second Line

  16. Improve overall survival, disease control, symptom palliation and quality of life • 27% increase in progression-free survival (PFS), a 55% increase in objective response rate (ORR), and 1.9-mo improvement in median overall survival (OS) second Line

  17. approved by FDA in 2004 and EMA in 2005 • Side effect: myelosuppression, fatigue, edema, neurotoxicity, hyperlacrimation, and changes in liver function. second Line

  18. Second-line systemic chemotherapy • docetaxel (again): for no definitive evidence of resistance to docetaxel • Cabazitaxel Third Line

  19. Cabazitaxel • tubulin-binding taxane • most common serious adverse events :hematological, including grade ≥3 neutropenia in 82% of patients, 8% febrile neutropenia and 5% deaths • prophylactic neutrophil growth factor support :older individuals and with significant prior radiotherapy Third Line

  20. Abiraterone • oral selective irreversibleinhibitor of the microsomal enzyme cytochrome P17 (17,20-lyase and 17α-hydroxylase) • expected increases in mineralocorticoids upstream of CYP17A • side effects: hypertension, hypokalemia, edema and fatigue treat with low dose glucocorticoids. Third Line

  21. The mechanism of action similar to ketoconazole • marked palliative and skeletal related benefits. • FDA approved for treatment Third Line

  22. Sipuleucel-T • Immunotherapy, FDA-approved agent • vaccine derived from CD54+ dendritic cells, (major antigen-presenting cells) • less than 10% exhibit a clinical, serologic or radiographic response • benefit patients with a lower disease burden and better performance status Third Line

  23. All three have an FDA indication in mCRPC • Docetaxeland sipuleucel-T immunotherapy: survival advantage • Abiraterone+ prednisone: radiographic progression-free survival benefits Third Line

  24. AUA Guideline

More Related